Drug Target Review2025-05-14T08:30:14
Metrion Biosciences has introduced a breakthrough NaV1.9 screening assay, aimed at overcoming historical challenges in pain research and advancing the development of non-opioid treatments.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-16T07:00:00Z
Author Dr Martin Baraibar
2026-11-13T07:00:00Z
Contributor Dr Panos Roussos, Drug Target Review
2026-11-06T07:26:00
Author Dr Tina Rogers
2026-10-21T14:02:00
Contributor Jim Corbett, Drug Target Review
2023-03-08T16:29:20
Sponsored by Bio-Techne
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2025-05-08T10:38:52
Sponsored by Takara Bio USA
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
Site powered by Webvision Cloud